Navigation Links
Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer
Date:6/16/2009

intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that dose-limiting toxicities may be experienced in future stages of the trial that will use higher doses of Cotara or the risk that results from larger trials may not be consistent with the results of earlier stage trials. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2008 and the quarterly report on Form 10-Q for the quarter ended January 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

    Contac
'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
2. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
5. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
6. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
7. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
8. Salugens Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis
9. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
10. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
11. Promising Data ATIR Studies Presented by NIH Investigators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... With the ability to record continuously at over 500 ... minutes, Fastec Imaging has brought the same ease-of-use of today’s ... a high speed camera that can be used as simply ... proclaims Matt Kearney, VP of Sales for Fastec Imaging. ... simplify the traditionally complicated workflow of a high speed camera. ...
(Date:7/23/2014)... Cambridge, MA (PRWEB) July 23, 2014 ... provider of innovative and comprehensive consultancy and pharma ... Research Excellence and Safety (ACRES) , a non-profit ... worldwide to build and maintain a global system ... strategic alliance collaboration to improve the expertise of ...
(Date:7/22/2014)... of Standards and Technology (NIST) and California Institute ... for an atomic clock that is based on ... The microcomb clock, featured on the cover of ... Optica ,* is the first demonstration of all-optical ... of optical frequencies to lower microwave frequencies. (Optical ...
(Date:7/22/2014)... York (PRWEB) July 22, 2014 Nuclear ... The heat produced by controlled fission chain reaction in ... steam pressure is used to drive a power- generating ... 19% of the world’s total electricity production. Nuclear reactor ... several under construction, planned and proposed nuclear reactor projects. ...
Breaking Biology Technology:Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 2Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 3'Comb on a chip' powers new NIST/Caltech atomic clock design 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 3
... Inc. (NYSE Amex: PIP ), a biodefense ... announced today that results from a second Phase II ... Annual Conference on Vaccine Research, being held in Baltimore, ... the National Foundation of Infectious Diseases.David P. Wright, President ...
... 28 Techne Corporation (Nasdaq: TECH ) announced ... dividend of $0.25 per share for the quarter ended March ... 22, 2009 to all common shareholders of record on May ... the Board of Directors on a quarterly basis.Techne,s Board of ...
... for Mycobacterium tuberculosis (TB) Expected to Highlight Broad On-Demand ... 28 Cepheid (Nasdaq: CPHD ) today ... Patient Management in the Era of Rapid Diagnostics ," ... Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking ...
Cached Biology Technology:PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 2PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 3PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 4PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 5PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 6PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 7Techne Corporation Declares Dividend and Announces an Increase in Its Share Repurchase Program 2Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 3Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 4Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 5
(Date:7/23/2014)... As of 2015, Springer will publish the International ... official journal of the Taiwan Fuzzy Systems Association (TFSA). ... global visibility in the area of fuzzy research., The ... to presenting high-quality papers that deal with the theory, ... gray systems and extension theory systems ranging from hardware ...
(Date:7/23/2014)... , July 23, 2014   MedNet ... specializing in clinical study management systems, is pleased ... a proven life sciences industry executive with over ... Operating Officer (COO).  Clareece will be responsible for ... growth, operational efficiency and quality product/service delivery.  ...
(Date:7/23/2014)... Streptococcus mutans , one of the principal bacteria ... in its genetic material over time, possibly coinciding ... humanity. This is highlighted in a study ... (UAB) and the Laboratorio Nacional de Genmica para ... in Mexico who, for the first time, have ...
Breaking Biology News(10 mins):MedNet Appoints Clareece West As Chief Operating Officer 2Ancient genetic material from caries bacterium obtained for the first time 2
... (NASDAQ: MASI ) today announced that its management ... Health Care Conference at the New York Palace Hotel in New York ... A live audiocast of the presentation will be available on ... the audiocast will be available following the live presentation. ...
... have suggested that climate change is causing additional stress to ... consider a significant reduction, or in some places elimination of ... growing degradation of grazing lands could be mitigated if large ... lands became free of use by livestock and "feral ungulates" ...
... CINCINNATIA University of Cincinnati (UC) Cancer Institute lung cancer ... be isolatedand then grownin a preclinical model, offering a ... target stem cells. John C. Morris, MD, ... 13, 2012, issue of PLOS One , a ...
Cached Biology News:Masimo to Present at 24th Annual Piper Jaffray Health Care Conference 2Masimo to Present at 24th Annual Piper Jaffray Health Care Conference 3Climate change increases stress, need for restoration on grazed public lands 2Climate change increases stress, need for restoration on grazed public lands 3Stem cell finding could advance immunotherapy for lung cancer 2